39 related articles for article (PubMed ID: 16138317)
1. Effects of sarizotan on the corticostriatal glutamate pathways.
Antonelli T; Fuxe K; Tomasini MC; Bartoszyk GD; Seyfried CA; Tanganelli S; Ferraro L
Synapse; 2005 Dec; 58(3):193-9. PubMed ID: 16138317
[TBL] [Abstract][Full Text] [Related]
2. The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats.
Smith S; Sergio J; Coyle M; Elder K; Centner A; Cohen S; Terry M; Lipari N; Glinski J; Wheelis E; Budrow C; Bishop C
Psychopharmacology (Berl); 2022 Jul; 239(7):2119-2132. PubMed ID: 35275226
[TBL] [Abstract][Full Text] [Related]
3. Effects of the Serotonin 5-HT
Newman-Tancredi A; Varney MA; McCreary AC
Neurochem Res; 2018 May; 43(5):1035-1046. PubMed ID: 29572645
[TBL] [Abstract][Full Text] [Related]
4. The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.
Carta M; Björklund A
J Neural Transm (Vienna); 2018 Aug; 125(8):1195-1202. PubMed ID: 29480391
[TBL] [Abstract][Full Text] [Related]
5. Role of adenosine A
Pinna A; Serra M; Morelli M; Simola N
J Neural Transm (Vienna); 2018 Aug; 125(8):1273-1286. PubMed ID: 29396609
[TBL] [Abstract][Full Text] [Related]
6. Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms.
Huang X; Yang J; Yang S; Cao S; Qin D; Zhou Y; Li X; Ye Y; Wu J
Oncotarget; 2017 Nov; 8(60):102705-102720. PubMed ID: 29254282
[TBL] [Abstract][Full Text] [Related]
7. Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.
Finlay CJ; Duty S; Vernon AC
Front Neurol; 2014; 5():95. PubMed ID: 24971074
[TBL] [Abstract][Full Text] [Related]
8. Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease.
Miguelez C; Morera-Herreras T; Torrecilla M; Ruiz-Ortega JA; Ugedo L
Front Neural Circuits; 2014; 8():21. PubMed ID: 24672433
[TBL] [Abstract][Full Text] [Related]
9. Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.
Dupre KB; Ostock CY; George JA; Eskow Jaunarajs KL; Hueston CM; Bishop C
ACS Chem Neurosci; 2013 May; 4(5):747-60. PubMed ID: 23496922
[TBL] [Abstract][Full Text] [Related]
10. Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.
Shimizu S; Ohno Y
Aging Dis; 2013 Feb; 4(1):1-13. PubMed ID: 23423244
[TBL] [Abstract][Full Text] [Related]
11. Striatal glutamate release in L-DOPA-induced dyskinetic animals.
Nevalainen N; Lundblad M; Gerhardt GA; Strömberg I
PLoS One; 2013; 8(2):e55706. PubMed ID: 23390548
[TBL] [Abstract][Full Text] [Related]
12. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.
Strecker K; Adamaszek M; Ohm S; Wegner F; Beck J; Schwarz J
J Neural Transm (Vienna); 2012 Nov; 119(11):1351-9. PubMed ID: 22569849
[TBL] [Abstract][Full Text] [Related]
13. Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.
Ostock CY; Dupre KB; Jaunarajs KL; Walters H; George J; Krolewski D; Walker PD; Bishop C
Neuropharmacology; 2011 Sep; 61(4):753-60. PubMed ID: 21635907
[TBL] [Abstract][Full Text] [Related]
14. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Dupre KB; Ostock CY; Eskow Jaunarajs KL; Button T; Savage LM; Wolf W; Bishop C
Exp Neurol; 2011 Jun; 229(2):288-99. PubMed ID: 21352823
[TBL] [Abstract][Full Text] [Related]
15. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.
Ohno Y
CNS Neurosci Ther; 2011 Feb; 17(1):58-65. PubMed ID: 21091640
[TBL] [Abstract][Full Text] [Related]
17. Presynaptic control of serotonin on striatal dopamine function.
Navailles S; De Deurwaerdère P
Psychopharmacology (Berl); 2011 Feb; 213(2-3):213-42. PubMed ID: 20953589
[TBL] [Abstract][Full Text] [Related]
18. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Paquette MA; Foley K; Brudney EG; Meshul CK; Johnson SW; Berger SP
Psychopharmacology (Berl); 2009 Jul; 204(4):743-54. PubMed ID: 19283364
[TBL] [Abstract][Full Text] [Related]
19. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Marin C; Aguilar E; Rodríguez-Oroz MC; Bartoszyk GD; Obeso JA
Psychopharmacology (Berl); 2009 Jun; 204(2):241-50. PubMed ID: 19159919
[TBL] [Abstract][Full Text] [Related]
20. Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Bishop C; Krolewski DM; Eskow KL; Barnum CJ; Dupre KB; Deak T; Walker PD
J Neurosci Res; 2009 May; 87(7):1645-58. PubMed ID: 19115412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
